Implementation of a novel strategy to increase participation of Black and Hispanic people in parkinsonism research Authors: Dalilah F Quintana Mora, Anya C McGoldrick, Yolfrankcis Mendez, Alessandra Cervera, Parul Agarwal, John F Crary, Ruth H Walker, Melissa J Nirenberg Published: 2026 ABSTRACT IntroductionBlack and Hispanic people are underrepresented in parkinsonism research leading to critical knowledge gaps and reduced quality of care.MethodsWe developed a novel, comprehensive clinical registry in which research eligibility, interest, and participation are actively tracked for all patients at our site to reduce selection bias and streamline recruitment. We also implemented targeted approaches to reduce psychosocial and sociocultural barriers to research participation of Black and Hispanic people. We then performed a retrospective chart review to test the hypothesis that these combined strategies would be associated with racially/ethnically unbiased research recruitment. All follow-up patients with degenerative parkinsonism seen at the Bronx Veterans Affairs Medical Center over a 19-month period were included in the analysis. Primary outcome measures were the approach and acceptance rates for CANPARK, a single-center prospective observational cohort study of American military veterans with parkinsonism.ResultsDuring the study window, 197 parkinsonism patients were seen, 192 were eligible for CANPARK [ages 53-91; 96.4% male; 29.7% Hoehn and Yahr ≥4; 25.0% atypical parkinsonism], 167 (87.0% of eligible patients) were invited to participate (similar in all racial/ethnic groups), and 128 of 159 patients who made a decision whether to participate (80.5%) agreed to enroll. Acceptance rates were comparable in Black (79.4%; p = 0.92) or Hispanic (87.5%; p = 0.43) versus White (80.2%) patients.ConclusionsUsing a novel, real-time clinical registry and targeted approaches, we achieved unbiased recruitment and high participation of Black and Hispanic patients in parkinsonism research. Future studies are needed to evaluate these approaches in other clinical settings. Introduction Racial and ethnic diversity in clinical research is critical for facilitating early diagnosis, optimizing treatment, and developing disease-modifying therapy applicable to all people with parkinsonian syndromes.1–4 Black and Hispanic patients, however, remain widely underrepresented in both interventional and observational parkinsonism research.5,6 These racial and ethnic disparities may disproportionately affect clinical trials because they require a higher degree of trust from patients, and often have narrower eligibility criteria, more frequent study visits, and greater susceptibility to investigator bias.5–9 Significant disparities are also present for brain donation, with very low participation of Black and Hispanic patients with neurodegenerative disorders.10,11 Of 5015 banked brains from donors with parkinsonism in the Mayo Clinic Brain Bank, only 25 (0.5%) of donors were Black and 78 (1.6%) were Hispanic (D.W. Dickson and M.E. Murray, personal communication, December 5, 2024). Similarly, of 516 banked brains at the Brain and Body Donation Program at the Banner Sun Health Research Institute, there were no Black and only 4 (0.77%) Hispanic donors; in their donor registry (n = 787), there were no Black and only 8 (1%) Hispanic donors (T. Beach and G.E. Serrano, personal communication, January 2, 2025). Post-mortem tissue analysis is critical for determining the underlying biological basis of these disorders and identifying potential differences related to racial/ethnic background.12–15 Many factors have been implicated in the low participation of Black and Hispanic patients in parkinsonism research and brain donation. Selection bias may occur due to false assumptions that patients are uninterested in research or would be unable to complete study activities.1,3,16–19 Lack of access or inability to afford medical care can be a major barrier in some healthcare systems, 1 as patients may remain undiagnosed or have less exposure to research opportunities. Delayed diagnosis may prevent Black and Hispanic patients from participating in clinical trials limited to early disease stages.20–23 Patients may be excluded from research studies because of medical comorbidities, which are generally higher in Black and Hispanic people, particularly those with lower socioeconomic status. 4 Mistrust related to past unethical and abusive treatment is also thought to be a major factor,24–26 though the extent to which this affects research participation has been questioned. 1 Potential reasons for disparities in brain donation include the invasiveness of the procedure, religious beliefs, sociocultural barriers, and misinformation.27,28 Multiple approaches have been recommended for increasing participation of Black and Hispanic patients in Parkinson's disease (PD) research. These include decentralizing research visits, simplifying and increasing flexibility of study protocols, covering travel costs, diversifying the research team, partnering with community leaders, and incentivizing recruitment of underrepresented populations.3,4,9,29–39 Implicit bias education programs have been helpful, but few have shown long-term benefit. 24 Real-time monitoring of patient schedules, coordination between investigators and research coordinators, and collaboration to encourage referrals from other clinicians have also been shown to improve recruitment of Black patients. 34 For brain donation, targeted efforts to recruit non-White patients have increased the participation of Black and Hispanic people, but have not been widely used.11,15,27 We designed a novel, comprehensive registry that is used in real time to prescreen charts, categorize and track research participation status for all patients, alert clinicians and research coordinators about action items prior to each clinic visit, and ensure that patients are given the opportunity to coordinate research participation with clinical appointments. We implemented this along with multiple targeted approaches to reduce known barriers to research participation of Black and Hispanic people. In this report, we test the hypothesis that these combined strategies would be associated with racially/ethnically unbiased recruitment and similar rates of participation of Black, Hispanic, and White patients in parkinsonism research. We focused on recruitment for a prospective observational cohort study at our center: Clinical and Neuropathological Characterization of Parkinsonism Related to Traumatic Brain Injury in Veterans (CANPARK). 40 Methods Study design and setting This was a retrospective chart review of veterans who had been seen at the James J. Peters (Bronx) Veterans Affairs (VA) Medical Center movement disorders clinic between December 2022 and June 2024. This site is a Regional Parkinson's and Movement Disorders Center covering the greater New York City area (Bronx, Brooklyn, Manhattan, and St. Albans [Queens] VA sites); Long Island, NY (Northport VA system); the Hudson Valley region of New York (Hudson Valley VA system); and the Finger Lakes regions of New York and Pennsylvania (Finger Lakes VA system). Participants The analysis included all patients with a clinical diagnosis of degenerative parkinsonism who were seen for a clinical follow-up visit during the designated time window, either on site (RHW or MJN) or via telemedicine (MJN). The clinic population is predominantly male (>93% overall; higher in older patients), as expected for military veterans. The study was approved by the James J. Peters VA Institutional Review Board with a waiver of informed consent. Development and implementation of a comprehensive prescreening registry We developed and implemented a prescreening registry that was initially used to collect basic clinical and demographic information about patients seen at our center. This was termed the “Standard of Care Registry” (SOCR) to clarify that it was being used in clinical practice and not itself a research study. Over time, the SOCR has evolved into a comprehensive registry (Microsoft Excel 365, Microsoft, Inc.) that is used in real time to systematically track and facilitate research participation of all patients seen at our center, determine site feasibility for future studies, streamline research recruitment, and reduce potential selection bias. Data collected in the SOCR include demographic information (including race/ethnicity), primary clinical diagnosis, relevant secondary diagnoses, primary VA site, and eligibility, interest, and participation in research. The patient's status is tracked separately for each study, and designated as “Enrolled”, “Interested” (patients who accepted participation in a study but have not yet enrolled), “Considering”, “Declined”, “Not eligible” (with a note as to why they are not eligible), “Ask” (for eligible patients who have not yet been invited to participate), or “Watch” (for patients with an unclear clinical diagnosis who may become eligible for the study in the future). Data validation with drop down menus is used to constrain the fields for primary diagnosis and research status to predefined options, facilitating sorting and searching of data. Calculated fields are used to dichotomize patients into those with (versus without) a parkinsonian syndrome and those with PD versus atypical parkinsonism. Free text fields are used to record other salient information, such as a patient's technological capabilities or the times at which they prefer to be contacted. Additional fields are added as needed to facilitate recruitment for new or anticipated research studies. One to two weeks prior to each clinic day, a research coordinator uses data from the SOCR to create a research tracking sheet. The tracking sheet includes a list of all scheduled patients, their participation status for each actively recruiting study (e.g., Enrolled, Interested, Not Eligible), their primary and secondary diagnoses, and other data relevant to research recruitment. Use of the tracking sheet enables research coordinators to contact interested patients in advance to synchronize research assessments with clinical visits and facilitate any necessary travel arrangements. A copy of the tracking sheet is emailed to clinicians prior to each clinic day, alerting them to any necessary research activities (e.g., patients who are due for a follow-up research visit, or those who should be recruited for specific studies). A research coordinator updates the SOCR after each clinic and at any other time in which there is a change in a patient's clinical diagnosis, research eligibility, or participation status. Targeted strategies to facilitate research participation of Black and Hispanic patients In addition to systematic prescreening with the SOCR, we implemented a combination of targeted strategies to facilitate participation of Black and Hispanic patients in the investigator-initiated research studies at our site. We design our studies with flexible research protocols and broad eligibility criteria. We assembled a diverse, bilingual (Spanish/English) research team to improve communication and reduce cultural barriers. We offer research participation to patients who are often excluded from studies, including those with significant cognitive impairment, residing in long-term care facilities, or in hospice. Patients who are unable to complete all study activities are given the opportunity to participate in a core subset of assessments with collateral information from care partners and surrogate consent. We reduce travel barriers by coordinating with patients in advance to synchronize research visits with clinical appointments, providing transportation assistance when needed, and offering virtual or telephone research visits for those who live at remote sites or are unable to travel. As a VA Medical Center, our site is part of a centralized system of free or low-cost medical care for United States military veterans, which reduces the financial and logistical barriers related to the high cost and complexity of navigating the civilian healthcare system in this country. Data collection Demographics Demographic data (including race, ethnicity, age, sex, and primary VA site), primary clinical diagnosis, Hoehn and Yahr stage, residence type (hospice, long-term care facility, or other), and research interest, eligibility, and enrollment status for each study were collected from the SOCR, with supplemental information obtained from the VA Computerized Patient Record System (CPRS) electronic medical record. Participants were categorized as: (1) Hispanic (any Hispanic or Latino background), (2) non-Hispanic Black (any Black or African American background), (3) non-Hispanic White, (4) non-Hispanic Asian/Pacific Islander, or (5) Other/Unknown, based on self-reported racial/ethnic identity. The primary VA site was defined as urban (NYC VA sites), suburban (Northport or Hudson Valley VA sites), or rural (Finger Lakes VA sites). The diagnosis of PD or an atypical parkinsonian syndrome was based on the assessment of the treating movement disorders specialist. Severe parkinsonism was defined as a Hoehn and Yahr stage ≥4. Primary outcome measures The primary outcome measures were the approach and acceptance rates for CANPARK by race and ethnicity. CANPARK is a VA-funded investigator-initiated prospective observational cohort study with broad eligibility criteria (age ≥18, clinical diagnosis of PD or atypical parkinsonism, no confounding medical conditions, and no neuroleptic use [other than quetiapine or clozapine] within the preceding 6 months). 40 The study includes baseline motor and non-motor assessments, optional sample collection for genetic and biomarker analysis, and consent for ongoing data collection from the medical record. Eligible patients who accepted participation in CANPARK were subsequently invited to participate in a genetics research study at our site and to enroll in a brain donor registry. Secondary outcome measures Secondary outcome measures were the approach and acceptance rates by race and ethnicity for: (1) the Veterans Parkinson's Disease Genetics Initiative (Vet-PD) study, 41 and (2) the Mount Sinai Neuropathology Brain Bank (NPBB) Donor Registry, among those who had agreed to participate in CANPARK. Vet-PD is a multicenter VA study sponsored by the Michael J. Fox Foundation for Parkinson's Research in which clinical data and DNA samples are collected from patients for inclusion in the Global Parkinson's Genetics Project (GP2) and other research repositories. 42 Most GP2 sites are limited to recruitment of patients with PD, but our site also included patients with atypical parkinsonism. Vet-PD has a particular focus on those from underrepresented racial and ethnic backgrounds. Eligibility criteria for Vet-PD are similar to those for CANPARK except that participants must also be able to provide a blood, saliva, or cheek swab DNA sample. The Mount Sinai NPBB donor registry is a prospective registry of patients interested in post-mortem brain donation to the NPBB, a clinical research repository focused on parkinsonism and other neurodegenerative diseases. Patients eligible for CANPARK are also eligible to participate in brain donation unless they have certain transmissible illnesses or are located at a remote site such that brain tissue could not be recovered and preserved within an acceptable postmortem interval. Definitions Approach rate was defined as the percentage of eligible patients who were invited by investigators to participate in CANPARK during the designated study window. Acceptance rate was defined as the percentage of those who were approached, made a decision whether to participate, and agreed to enroll during the study window (and had either enrolled or were pending enrollment). Enrollment rate was defined as the percentage of patients who agreed to participate in CANPARK who had enrolled within 6 months of the end of the study window. Statistical analysis Participant characteristics were summarized using frequencies and percentages for categorical variables and medians with interquartile ranges (IQRs) for continuous variables. The primary outcomes were approach and acceptance rates for CANPARK by race and ethnicity. Enrollment rates 6 months after the close of the study window were calculated for those who had accepted CANPARK study participation. Among participants who accepted CANPARK, study-specific approach, acceptance, and enrollment rates were calculated for the Vet-PD study and the NPBB brain donor registry using the same operational definitions. Bivariate comparisons of recruitment outcomes by race/ethnicity (non-Hispanic Black vs. non-Hispanic White; Hispanic vs. non-Hispanic White) and by prespecified subgroups (age, sex, diagnosis [PD vs. atypical parkinsonism], parkinsonism severity [Hoehn and Yahr ≥4 vs. < 4], and VA site category [urban/suburban vs. rural]) were performed using chi-square tests or Fisher's exact tests as appropriate based on expected cell counts. Due to the small number of non-Hispanic Asian/Pacific Islander patients, this group was excluded from race/ethnicity and other comparisons. Statistical significance was defined as a two-sided α=0.05. Analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). Results Study population A total of 197 patients with degenerative parkinsonism were seen for a clinical follow-up appointment during the study window. Of these, 97.5% (n = 192) were eligible to participate in CANPARK and 5 were excluded due to the presence of a confounding medical condition (n = 4) or use of a neuroleptic other than quetiapine or clozapine within the prior 6 months (n = 1; Figure 1A). The age range of eligible patients was 53–91 years (median 76 years, IQR 8). Almost all eligible patients were male (96.4%, n = 185) (Table 1), consistent with the male predominance of the clinic and veteran population of this age range. The racial and ethnic breakdown of those who were eligible for CANPARK (21.9% Black, 20.3% Hispanic, 56.8% White, 1.0% Asian/Pacific Islander) was comparable to that of the overall movement disorders clinic (23.5% Black, 17.4% Hispanic, 56.0% White, 0.4% Asian/Pacific Islander). Study eligibility and acceptance by race/ethnicity A. Flowchart showing CANPARK eligibility and acceptance rates in all patients with degenerative parkinsonism. Six months after the end of the study window, 78.1% (n = 100) of the 128 patients who accepted participation in CANPARK had enrolled, 18.8% (n = 24) were pending enrollment, and 4 (all White) declined. B. Flowchart showing Vet-PD eligibility and acceptance rates in patients who had accepted participation in CANPARK. Of the eligible patients who decided whether to participate in Vet-PD, 97.2% chose to join the study. Six months after the end of the study window, 82.9% (n = 87) of the 105 patients who agreed to participate in Vet-PD had enrolled, 16 were pending enrollment, and 2 (both White) declined. C: Flowchart showing brain donation eligibility and acceptance rates in patients who had accepted participation in CANPARK. Of the eligible patients who decided whether to participate in brain donation, 54% chose to join the donor registry. Six months after the end of the study window, 85.2% (n = 46) of the 54 patients who accepted participation had enrolled in the brain donor registry, 7 were pending enrollment, and 1 (Hispanic) declined. The “not yet approached” groups included cases in which the discussion of research opportunities was deferred due to factors such as insufficient time at the visit or active medical, social, or psychiatric issues. Abbreviations: CANPARK, Clinical and Neuropathological Characterization of Parkinsonism Related to Traumatic Brain Injury in Veterans study; Vet-PD, Veterans Parkinson's Disease Genetics Initiative study. Table 1.Characteristics of patients eligible for CANPARK.Eligible patient populationN = 192Age (years), median (IQR)76 (8)Age Category, % (n) < 80 Years77.1% (148) ≥ 80 Years22.9% (44)Race/Ethnicity, % (n) Black, non-Hispanic21.9% (42) Hispanic20.3% (39) White, non-Hispanic56.8% (109) Asian/Pacific Islander, non-Hispanic1.0% (2)Sex, % (n) Male96.4% (185) Female3.6% (7)Diagnosis, % (n) Parkinson's disease75.0% (144) Atypical parkinsonism Atypical parkinsonism, unspecified3.1% (6) Corticobasal degeneration1.0% (2) Diffuse Lewy body disease9.9% (19) Frontotemporal dementia2.6% (5) Multiple system atrophy1.0% (2) Progressive supranuclear palsy7.3% (14)Hoehn & Yahr Stage, % (n) < 4 (mild-moderate)70.3% (135) 4-5 (severe)29.7% (57)VA Site, % (n) Urban Bronx VA53.1% (102) Brooklyn VA8.3% (16) Manhattan VA3.6% (7) St. Albans VA1.0% (2) Suburban Long Island VA18.8% (36) Hudson Valley VA2.6% (5) Rural Finger Lakes VA12.5% (24)Demographic and clinical characteristics of patients who were eligible for the CANPARK study. Male predominance reflects the demographics of the overall movement disorders clinic.Abbreviations: CANPARK, Clinical and Neuropathological Characterization of Parkinsonism Related to Traumatic Brain Injury in Veterans study. VA, Veterans Affairs. Characteristics of patients eligible for CANPARK. Demographic and clinical characteristics of patients who were eligible for the CANPARK study. Male predominance reflects the demographics of the overall movement disorders clinic. Abbreviations: CANPARK, Clinical and Neuropathological Characterization of Parkinsonism Related to Traumatic Brain Injury in Veterans study. VA, Veterans Affairs. Of 192 eligible patients, approximately two-thirds (66.1%, n = 127) were from NYC VA sites and usually seen on-site at the Bronx VA. Other eligible patients were from suburban (21.4%) or rural (12.5%) VA sites and almost always seen by telemedicine, either at the participant's home (or other private location) facilitated by the patient or care partner, or at a local VA Community-Based Outpatient Clinic (CBOC) facilitated by VA staff. Most participants (75%) had a clinical diagnosis of PD; the other 25% had an atypical parkinsonian syndrome. About 30% of eligible patients had severe parkinsonism. The demographic and clinical features of the eligible study population are summarized in Table 1. CANPARK approach rate To assess the efficacy of the SOCR in attaining unbiased recruitment, we looked at approach rates by race and ethnicity. Of 192 eligible patients, 167 were invited to participate in CANPARK (87.0% approach rate; Figure 1A), with similar approach rates in Black (90.5%, p = 0.59) or Hispanic (84.6%, p = 0.80) versus White patients (86.2%). Asian/Pacific Islander patients had a very low representation in the cohort (1.2%, n = 2) and were excluded from further comparisons. Approach rates were similar for the oldest-old versus other age groups (87.0% vs. 86.8%), men versus women (86.3% vs. 100.0%), PD versus atypical parkinsonism (86.0% vs. 89.4%), severe versus mild-moderate parkinsonism (81.8% vs. 88.9%), and those from metropolitan (urban or suburban) versus rural VA sites (87.4% vs. 83.3%). Reasons for which a patient may not have been approached included insufficient time at the appointment or active medical, social, or psychiatric issues such that a discussion of research opportunities would not have been appropriate. CANPARK acceptance and enrollment rates To evaluate the efficacy of our recruitment strategies in reducing barriers to research participation, we examined the acceptance rates of patients in underrepresented groups. Of the patients who made a decision whether to participate in CANPARK, 80.5% agreed to enroll (Figure 1A), with similar acceptance rates in Black (79.4%; p = 0.92) or Hispanic (87.5%; p = 0.43) versus White (80.2%) patients (Table 2). There was no statistically significant difference in acceptance rates in men versus women, though analysis was limited by the small number of women in the clinic population. Acceptance rates were comparable for the oldest-old versus younger patients, atypical parkinsonism versus PD, severe versus mild-to-moderate parkinsonism, and those from metropolitan versus rural VA sites (Table 2). Two patients who accepted participation in CANPARK were in hospice and 9 others were in long-term care facilities. Six months after the end of the study window, 78.1% (n = 100) of the 128 patients who accepted participation in CANPARK had enrolled, 24 were pending enrollment, and 4 (all White) subsequently declined. Table 2.Comparison of patients who accepted versus declined participation in CANPARK.AcceptedDeclinedp-valuen = 128n = 29Race/Ethnicity, % (n)0.66 Black, non-Hispanic79.4% (27)20.6% (7) Hispanic87.5% (28)12.5% (4) White, non-Hispanic80.2% (73)19.8% (18)Age Category, % (n)0.75 < 80 Years82.1% (92)17.9% (20) ≥ 80 Years80.0% (36)20.0% (9)Sex, % (n)0.35 Male80.7% (121)19.3% (29) Female100% (7) 0% (0)Diagnosis, % (n)0.67 Parkinson's disease80.5% (95)19.5% (23) Atypical parkinsonism84.6% (33)15.4% (6)Hoehn & Yahr Stage, % (n)0.98 < 481.6% (93)18.4% (21) 4-581.4% (35)18.6% (8)VA Site, % (n)0.37 Rural90.0% (18)10.0% (2) Urban/suburban80.3% (110)19.7% (27)Demographic and clinical characteristics of patients who accepted versus declined participation in the CANPARK study. Acceptance rates were similarly high in all racial/ethnic groups. Asian/Pacific Islander patients (n = 2) were excluded from analysis due to their low representation in the cohort. Abbreviation: CANPARK, Clinical and Neuropathological Characterization of Parkinsonism Related to Traumatic Brain Injury in Veterans study. VA, Veterans Affairs. Comparison of patients who accepted versus declined participation in CANPARK. Demographic and clinical characteristics of patients who accepted versus declined participation in the CANPARK study. Acceptance rates were similarly high in all racial/ethnic groups. Asian/Pacific Islander patients (n = 2) were excluded from analysis due to their low representation in the cohort. Abbreviation: CANPARK, Clinical and Neuropathological Characterization of Parkinsonism Related to Traumatic Brain Injury in Veterans study. VA, Veterans Affairs. Vet-PD approach, acceptance, and enrollment rates Of the 128 patients who accepted participation in CANPARK, 127 (99.2%) were eligible for Vet-PD, and 1 was not eligible because they were deceased before the start of the Vet-PD study (Figure 1B). Of the 127 eligible patients, 86.6% (n = 110) were invited to participate in Vet-PD, with no significant racial/ethnic differences in approach rates for Black (88.9%; p = 0.55) or Hispanic (96.4%, p = 0.10) versus White (81.5%) patients. Of the patients who made a decision whether to enroll in Vet-PD, 97.2% (n = 105) accepted. Acceptance rates were comparable in Black (100%, p = 1.00) and Hispanic (96.3%, p = 1.00) versus White (96.6%) patients (Figure 1B). Six months after the end of the study window, 82.9% (n = 87) of the 105 patients who accepted participation in Vet-PD had enrolled, 16 were pending enrollment, and 2 (both White) subsequently declined. Brain donor registry approach, acceptance, and enrollment rates Of the 128 patients who accepted participation in CANPARK, 97.7% (n = 125) were eligible to participate in the NPBB donor registry and 3 were not eligible because of geographic distance from the brain bank (n = 2) or because they were deceased before they could be invited to participate (n = 1) (Figure 1C). Of the 125 eligible patients, 91.2% (n = 114) were invited to participate in the donor registry, with comparable approach rates in Black (88.9% p = 0.70) or Hispanic (92.3%; p = 1.00) versus White (91.7%) patients. Of the patients who made a decision whether to enroll in the donor registry, 54.0% (n = 54) agreed to participate (Figure 1C). There were no significant differences in acceptance rates in Black (40.0%, p = 0.13) or Hispanic (50.0%, p = 0.47) versus White (60.0%) patients. Six months after the end of the study window, 85.2% (n = 46) of the 54 patients who agreed to participate in the donor registry had enrolled, including 3 (all White) who came to autopsy. Seven patients were still pending enrollment, and 1 patient (Hispanic) subsequently declined. Discussion A major limitation of parkinsonism research is that participation has been largely restricted to non-Hispanic people of White, European ancestry. Investigators have explored potential barriers to participation1,3,16,18–21,23 and implemented different approaches to increase the racial/ethnic diversity of research participants,4,9,11,15,24,27,29–37 but even with these efforts, research participation of Black and Hispanic patients has remained low. Addressing these disparities is critical for generating generalizable clinical and scientific knowledge, optimizing disease management, and increasing patients’ confidence in available treatments. Using the SOCR, our comprehensive, high-throughput registry, to actively track research participation, we achieved notably high approach rates (87%) for CANPARK that were similar in all racial/ethnic groups. This indicates that use of the SOCR successfully mitigated against potential racial/ethnic recruitment bias. In addition, the combined use of the SOCR with specific, targeted strategies to reduce participation barriers for Black and Hispanic patients resulted in CANPARK acceptance and enrollment rates that were very high (81.5% overall acceptance rate) and similar in Black, Hispanic, and White patients. This shows that when participation barriers were addressed, Black and Hispanic patients who were invited to enroll had strong interest in research participation. The proportional representation of Black and Hispanic patients in CANPARK will increase the generalizability of the study findings and their specific relevance to Black and Hispanic patients. The design features of the SOCR facilitated efficient and unbiased recruitment, including a detailed report provided to clinicians prior to each clinic day that enabled them to address (or defer) action items expeditiously and with reduced cognitive burden. This made it possible to offer research participation to a larger number of patients within the time constraints of a clinical appointment. It also ensured that research opportunities were presented by a clinician who had an established relationship with the patient; this likely increased patients’ trust, which may have contributed to the high acceptance rates. Research coordinators were also able to reduce travel burden by contacting patients in advance, offering the opportunity to synchronize research visits with clinical appointments and providing necessary transportation assistance. While the focus of this study was on Black and Hispanic veterans, the recruitment strategies that we used facilitated significant participation of other traditionally underrepresented groups, 43 including those with severe parkinsonism, the oldest-old, and those living in rural areas, with acceptance rates in each group that were proportional to their representation in the clinic. We also succeeded in enrolling patients who were in hospice or long-term care facilities, populations that are usually excluded from research. 44 Acceptance rates were comparable in atypical parkinsonism and PD, indicating that our recruitment strategies are applicable to more than one neurodegenerative disorder. Use of the SOCR also enabled us to achieve high participation of Black and Hispanic patients in other research studies at our center. Almost all patients who accepted participation in CANPARK subsequently agreed to participate in Vet-PD, enabling us to rapidly enroll patients in this multicenter genetics study. Accordingly, despite the small size of our clinic, we were the first of 21 non-lead sites to achieve both the first- and the second-year recruitment goals for the Vet-PD study [Cyrus Zabetian, MD; personal communication]. The high enrollment rate of CANPARK participants in the Vet-PD study suggests that these patients were satisfied with their experience in clinical research, thus representing a potential “clinical trial-ready” cohort. 45 Using the SOCR and our other recruitment strategies, we achieved similarly high participation of Black and Hispanic patients in the brain donor registry, despite the invasiveness of the brain donation process and significant sociocultural barriers.27,28 In the 3 years after we implemented the SOCR for brain donation, 28.3% (n = 15) of 53 patients who enrolled in the brain donor registry were non-White (6 Black, 8 Hispanic, 1 American Indian) compared with only 11.8% (n = 4) of 34 patients who had enrolled in the preceding 3 years. Prior to implementation of the SOCR for our VA brain donation program, all 18 banked brains were from White donors; since then, we have collected 3 brains from Black donors and 2 from Hispanic donors [unpublished observations]. Strengths of this study include the racial, ethnic, geographic, and clinical diversity of the study population and availability of comprehensive, prospectively collected data about research eligibility, interest, and participation in the SOCR. Limitations include the fact that this was a single-center study of a predominantly male population of United States military veterans, so the results may not be generalizable to other populations such as women and non-veterans. The VA also offers a unique healthcare model, with lower costs, centralized care, and reduced logistical barriers; for this reason, the findings may not be applicable to other clinical settings. Factors that influence decisions about research participation may also differ in veterans compared with civilians; while some veterans are motivated by a sense of duty and altruism, many are reluctant to participate due to privacy concerns, dissatisfaction with the government, or lack of trust in federal agencies.46,47 Because the SOCR was deployed before we began research recruitment, we are unable to compare recruitment rates from before versus after it was implemented, establish causality, or determine the reasons for which specific patients chose to accept or decline research participation. These topics would be valuable areas of future investigation. In summary, when we used a combination of the SOCR with other strategies to reduce research participation barriers, Black and Hispanic patients participated in parkinsonism research at rates that were similarly high to those of White patients. Future studies are needed to test these combined recruitment strategies in other clinical settings, patient populations, and interventional studies.